Checkmate Pharmaceuticals Inc.

10.50+0.0200+0.19%Vol 59.99K1Y Perf 56.89%
May 27th, 2022 16:00 DELAYED
BID10.48 ASK10.50
Open10.49 Previous Close10.48
Pre-Market- After-Market-
 - -  - -%
Target Price
11.33 
Analyst Rating
Moderate Buy 1.67
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
100.00 
Earnings Rating
Market Cap231.40M 
Earnings Date
12th May 2022
Alpha0.09 Standard Deviation0.53
Beta-4.83 

Today's Price Range

10.4810.50

52W Range

2.0010.50

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
-
1 Month
0.10%
3 Months
238.71%
6 Months
238.71%
1 Year
56.89%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CMPI10.500.02000.19
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.73-0.730.00
Q04 2021--0.62-
Q03 2021-0.71-0.692.82
Q02 2021-0.94-0.886.38
Q01 2021-0.75-0.6513.33
Q03 2020-0.40-0.84-110.00
Q02 2020--7.37-
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.73
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume59.99K
Shares Outstanding22.04K
Shares Float15.31M
Trades Count266
Dollar Volume629.55K
Avg. Volume211.51K
Avg. Weekly Volume128.66K
Avg. Monthly Volume291.07K
Avg. Quarterly Volume214.79K

Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) stock closed at 10.5 per share at the end of the most recent trading day (a 0.19% change compared to the prior day closing price) with a volume of 59.99K shares and market capitalization of 231.40M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. Checkmate Pharmaceuticals Inc. CEO is Barry A. Labinger.

The one-year performance of Checkmate Pharmaceuticals Inc. stock is 56.89%, while year-to-date (YTD) performance is 265.85%. CMPI stock has a five-year performance of %. Its 52-week range is between 2 and 10.5, which gives CMPI stock a 52-week price range ratio of 100.00%

Checkmate Pharmaceuticals Inc. currently has a PE ratio of -3.60, a price-to-book (PB) ratio of 4.21, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -67.66%, a ROC of -75.52% and a ROE of -75.44%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Checkmate Pharmaceuticals Inc., there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.73 for the next earnings report. Checkmate Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Checkmate Pharmaceuticals Inc. is Moderate Buy (1.67), with a target price of $11.33, which is 0.00% compared to the current price. The earnings rating for Checkmate Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Checkmate Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Checkmate Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 57.65, ATR14 : 0.12, CCI20 : 95.34, Chaikin Money Flow : 0.32, MACD : 0.77, Money Flow Index : 73.43, ROC : 1.25, RSI : 88.99, STOCH (14,3) : 100.00, STOCH RSI : 0.18, UO : 56.93, Williams %R : 0.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Checkmate Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
1 (33.33 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Strong Buy
1.00

Checkmate Pharmaceuticals Inc.

Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.

CEO: Barry A. Labinger

Telephone: +1 617 682-3625

Address: 245 Main Street, Cambridge 02142, MA, US

Number of employees: 25

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

47%53%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

TipRanks News for CMPI

Tue, 12 Apr 2022 03:15 GMT Checkmate Pharmaceuticals (CMPI) Receives a Buy from BTIG

- TipRanks. All rights reserved.

News

Stocktwits